Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b/2 Study of an Immunotherapeutic Vaccine, DPX-Survivac With Low Dose Cyclophosphamide and Epacadostat (INCB024360) in Patients With Recurrent Ovarian Cancer

Next Previous
Trial Profile

A Phase 1b/2 Study of an Immunotherapeutic Vaccine, DPX-Survivac With Low Dose Cyclophosphamide and Epacadostat (INCB024360) in Patients With Recurrent Ovarian Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 15 Feb 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cyclophosphamide (Primary) ; Epacadostat (Primary) ; Maveropepimut-S (Primary)
  • Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms DeCidE; DeCidE1; DeCidE1
  • Sponsors IMV

Most Recent Events

  • 12 Feb 2024 According to a BioVaxys media release, data from this study were presented at the 2023 SGO Annual Meeting on Women's Cancer .
  • 01 May 2023 Results (n=22; March 2019 to June 2021) assessing the safety and effectiveness of maveropepimut-S with cyclophosphamide in patients with recurrent ovarian cancer, published in the Clinical Cancer Research.
  • 19 Apr 2023 T cell repertoires of pre- and on-treatment (on-Tx) tumor biopsies of patients from this trial to further investigate the fate of T cells elicited by the MVP-S based therapy presented at the 114th Annual Meeting of the American Association for Cancer Research

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top